GLP-1受体激动剂在2型糖尿病患者管理中的有效性

IF 1.6 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Atencion Primaria Pub Date : 2025-09-08 DOI:10.1016/j.aprim.2025.103354

Ferran Bejarano Romero , Vicente Aragó Molés , Daniel Morón Porrúa , Eva López Guerrero , Helena Suñer Barriga , Laura Canadell Vilarrasa

{"title":"GLP-1受体激动剂在2型糖尿病患者管理中的有效性","authors":"Ferran Bejarano Romero , Vicente Aragó Molés , Daniel Morón Porrúa , Eva López Guerrero , Helena Suñer Barriga , Laura Canadell Vilarrasa","doi":"10.1016/j.aprim.2025.103354","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effectiveness of GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus and to describe their clinical characteristics.</div></div><div><h3>Design</h3><div>Retrospective cohort study based on electronic health records.</div></div><div><h3>Site</h3><div>Health centres of the Primary and Community Care Management (GAPiC) Camp de Tarragona.</div></div><div><h3>Participants</h3><div>Patients aged ≥18 years with a diagnosis of type 2 diabetes mellitus on treatment with an GLP-1 RA.</div></div><div><h3>Main measurements</h3><div>Demographic variables, glycosylated haemoglobin (HbA1c) and weight/BMI were collected to assess effectiveness; and clinical variables were recorded to assess safety.</div></div><div><h3>Results</h3><div>A total of 1227 patients (50.2% male) were included. A mean average HbA1c% reduction of 0.50% in HbA1c (p<0.001), weight reduction of 3.08kg weight (p<0.001) and BMI reduction of 0.99kg/m<sup>2</sup> (p<0,001) were observed after 472 days of average treatment.</div></div><div><h3>Conclusions</h3><div>GLP-1 RAs are effective in glycemic control and weight reduction in clinical practice. The results are consistent with international studies, although somewhat lower than pivotal trials.</div></div>","PeriodicalId":55435,"journal":{"name":"Atencion Primaria","volume":"57 11","pages":"Article 103354"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efectividad de los agonistas del receptor GLP-1 en el manejo de pacientes diabéticos tipo 2\",\"authors\":\"Ferran Bejarano Romero , Vicente Aragó Molés , Daniel Morón Porrúa , Eva López Guerrero , Helena Suñer Barriga , Laura Canadell Vilarrasa\",\"doi\":\"10.1016/j.aprim.2025.103354\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To evaluate the effectiveness of GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus and to describe their clinical characteristics.</div></div><div><h3>Design</h3><div>Retrospective cohort study based on electronic health records.</div></div><div><h3>Site</h3><div>Health centres of the Primary and Community Care Management (GAPiC) Camp de Tarragona.</div></div><div><h3>Participants</h3><div>Patients aged ≥18 years with a diagnosis of type 2 diabetes mellitus on treatment with an GLP-1 RA.</div></div><div><h3>Main measurements</h3><div>Demographic variables, glycosylated haemoglobin (HbA1c) and weight/BMI were collected to assess effectiveness; and clinical variables were recorded to assess safety.</div></div><div><h3>Results</h3><div>A total of 1227 patients (50.2% male) were included. A mean average HbA1c% reduction of 0.50% in HbA1c (p<0.001), weight reduction of 3.08kg weight (p<0.001) and BMI reduction of 0.99kg/m<sup>2</sup> (p<0,001) were observed after 472 days of average treatment.</div></div><div><h3>Conclusions</h3><div>GLP-1 RAs are effective in glycemic control and weight reduction in clinical practice. The results are consistent with international studies, although somewhat lower than pivotal trials.</div></div>\",\"PeriodicalId\":55435,\"journal\":{\"name\":\"Atencion Primaria\",\"volume\":\"57 11\",\"pages\":\"Article 103354\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atencion Primaria\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0212656725001404\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atencion Primaria","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0212656725001404","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目的评价GLP-1受体激动剂（GLP-1 RAs）治疗2型糖尿病的疗效，探讨其临床特点。设计基于电子健康记录的回顾性队列研究。塔拉戈纳营地初级保健和社区保健管理（GAPiC）现场保健中心。受试者年龄≥18岁，诊断为2型糖尿病，接受GLP-1 RA治疗。主要测量方法收集人口学变量、糖化血红蛋白（HbA1c）和体重/BMI来评估疗效；并记录临床变量以评估安全性。结果共纳入1227例患者，其中男性50.2%。平均治疗472天后，HbA1c平均降低了0.50% (p < 0.001)，体重减轻了3.08 kg体重（p < 0.001）， BMI降低了0.99 kg/m2 （p < 001）。结论glp -1 RAs在临床上具有良好的血糖控制和减肥作用。结果与国际研究一致，尽管比关键试验低一些。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efectividad de los agonistas del receptor GLP-1 en el manejo de pacientes diabéticos tipo 2

Objective

To evaluate the effectiveness of GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus and to describe their clinical characteristics.

Design

Retrospective cohort study based on electronic health records.

Site

Health centres of the Primary and Community Care Management (GAPiC) Camp de Tarragona.

Participants

Patients aged ≥ 18 years with a diagnosis of type 2 diabetes mellitus on treatment with an GLP-1 RA.

Main measurements

Demographic variables, glycosylated haemoglobin (HbA1c) and weight/BMI were collected to assess effectiveness; and clinical variables were recorded to assess safety.

Results

A total of 1227 patients (50.2% male) were included. A mean average HbA1c% reduction of 0.50% in HbA1c (p < 0.001), weight reduction of 3.08 kg weight (p < 0.001) and BMI reduction of 0.99 kg/m² (p < 0,001) were observed after 472 days of average treatment.

Conclusions

GLP-1 RAs are effective in glycemic control and weight reduction in clinical practice. The results are consistent with international studies, although somewhat lower than pivotal trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Atencion Primaria 医学-医学：内科

CiteScore

2.90

自引率

8.00%

发文量

156

审稿时长

33 days

期刊介绍： Atención Primaria es una revista que publica trabajos de investigación relativos al ámbito de la atención primaria de salud. Desde el punto de vista conceptual, Atención Primaria asume el nuevo modelo de atención primaria de salud, orientado no sólo a la curación de la enfermedad, sino también a su prevención y a la promoción de la salud, tanto en el plano individual como en el de la familia y la comunidad. En estos nuevos aspectos que definen el modelo de atención primaria de salud es en los que se centran los trabajos de investigación que publica Atención Primaria, la primera revista de originales española creada para recoger y difundir la producción científica realizada desde los centros de atención primaria de salud sobre cuestiones como protocolización de la asistencia, programas de prevención, seguimiento y control de pacientes crónicos, organización y gestión de la asistencia primaria, entre otros.